Redcliffe Labs has divested its fertility services business, Crysta IVF, to Moon Care Private Limited, the healthcare arm of MMG Group, in a strategic move aimed at sharpening its focus on diagnostics and preventive healthcare.

The transaction underscores the diagnostics chain’s intent to deepen its presence in technology-led testing services while allowing Crysta IVF to pursue its next phase of growth under a dedicated fertility care platform. 

The deal enables Redcliffe Labs to consolidate resources around its core diagnostics business, where it has been scaling rapidly through preventive screening, home sample collection, and AI-enabled health insights. For Crysta IVF, the acquisition offers an opportunity to expand its reproductive health footprint with strategic backing from MMG Group, marking the conglomerate’s first formal entry into healthcare services. 

“Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare,” said Aditya Kandoi, Founder and CEO of Redcliffe Labs. He noted that the divestment would help the company intensify its focus on adding “healthier years to people’s lives” through accessible diagnostics. Kandoi added that Crysta IVF, which began as an operate-and-manage model in 2021, evolved into a scalable network of self-owned centres and achieved profitability in a relatively short period. 

For MMG Group, the acquisition is positioned as a platform bet on India’s expanding fertility services market. “We are delighted to welcome Crysta IVF into the Moon Care ecosystem,” said Sanjeev Agarwal, Chairman, MMG Group, adding that the group plans to make fertility care more accessible and technology-driven while expanding treatment access nationwide. 

Advisory firm Alvarez & Marsal acted as the exclusive advisor to the transaction. Mohit Khullar, Managing Director and Leader – Corporate Finance, Alvarez & Marsal India, said the transaction highlights sustained investor confidence in India’s healthcare services ecosystem and reinforces the growth potential within the IVF segment.